All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma Hub is an independent medical education platform, sponsored by Roche, AbbVie, BeOne, Miltenyi Biomedicine, Thermo Fisher, Nurix Therapeutics and Caribou Biosciences and supported through independent educational grants from Incyte, Bristol Myers Squibb, Pfizer and Takeda Pharmaceuticals U.S.A., Inc. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account to access:
Bookmark & personalize site content
Receive alerts for new content in your areas of interest
View lymphoma & CLL content recommended for you
The FDA grants mogamulizumab Breakthrough Therapy Designation for relapsed/refractory Cutaneous T-Cell Lymphoma
On 25th August 2017, mogamulizumab was granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with Mycosis Fungoides (MF) or Sézary Syndrome (SS) and who have received one or more prior systemic therapies.
Mogamulizumab is a humanized monoclonal antibody, which targets and blocks C-C Chemokine Receptor 4 (CCR4) thereby initiating antibody dependent cellular cytotoxicity against CCR4-positive T-cells as well as inhibiting chemokine-mediated cellular migration, T-cell proliferation, and chemokine-mediated angiogenesis.
The BTD was granted based on results from the mogamulizumab anti-CCR4 antibody versus comparator in CTCL (MAVORIC) trial; a phase III, open-label, multicenter, randomized trial of mogamulizumab versus vorinostat in patients with relapsed/refractory MF or SS (NCT01728805). The study is taking place in the US, Australia, Japan, and Europe. Overall, 372 patients have been included in the study and estimated study completion is December 2018.
References
- Markets Insider. US Food and Drug Administration Grants Breakthrough Therapy Designation for Mogamulizumab for the Treatment of Mycosis Fungoides and Sézary Syndrome. 2017 Aug 25. http://markets.businessinsider.com/news/stocks/US-Food-and-Drug-Administration-Grants-Breakthrough-Therapy-Designation-for-Mogamulizumab-for-the-Treatment-of-Mycosis-Fungoides-and-S%C3%A9zary-Syndrome-1002284390. [Accessed 2017 Aug 25].
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
This content is accurate as of the date of publication and is not updated retrospectively. Please refer to the latest available evidence, guidelines, and relevant regulatory information when making clinical decisions.
Your opinion matters
When selecting the next therapy for patients with R/R MCL after BTKi progression, what is your most important consideration?